Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576847 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
A Phase 3 study of Rosacea, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
- 20
- Study locations
NCT02576847: Completed Phase 3 study of Rosacea, sponsored by Maruho Co..
NCT02576847 is a Phase 3 study of Rosacea that has completed, run by Maruho Co.. The registered enrollment target is 307 participants, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576847, a Phase 3 study of Rosacea, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
Primary Outcome
Number of subjects with 1 or more treatment-related Treatment-Emergent Adverse Events
Conditions Studied
Interventions
- DRUG Omiganan
Study Locations (20)
Florida
- - Miami
- - Miramar
- - Tampa
Indiana
- - Carmel
- - Indianapolis
- - Plainfield
Texas
- - Dallas
- - Pflugerville
- - Webster
California
- - Fremont
Illinois
- - Arlington Heights
Massachusetts
- - Watertown
New Mexico
- - Albuquerque
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 3 |
What the finished NCT02576847 record still lists
NCT02576847 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Omiganan is the first listed.
NCT02576847 names 20 study sites across 14 states, led by Florida, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02576847 about?
NCT02576847 is a clinical study titled "Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel". This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
What is the current status of trial NCT02576847?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2015-10. Estimated completion is 2018-02-08.
What conditions does trial NCT02576847 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02576847?
The interventions under investigation include: Omiganan (DRUG).
Who is sponsoring clinical trial NCT02576847?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576847 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02576847's enrollment target sits among peer trials
307 6th of 23 higher than 18 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia